Research ArticleAccepted Article
The Longitudinal Course of Fatigue in Anca Associated Vasculitis
Lucy O’Malley, Katie Druce, Dimitrios Chanouzas, Matthew Morgan, Rachel Jones, David Jayne, Neil Basu and Lorraine Harper
The Journal of Rheumatology July 2019, jrheum.190113; DOI: https://doi.org/10.3899/jrheum.190113
Lucy O’Malley
From the Institute of Clinical Sciences, University of Birmingham, Birmingham B15 2TT; Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom; Department of Medicine, University of Cambridge; Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow. This work was supported by Vifor Pharma (previously Aspreva Pharmaceuticals) who provided a research grant to cover the trial and MMF costs for MYCYC and F. Hoffmann–La Roche who provided the rituximab and a research grant that contributed to trial costs for RITUXIVAS. The funding sources had no role in the design and conduct of the study, collection, management, analysis and interpretation of the data, preparation, review, or approval of the manuscript, and decision to submit the manuscript for publication. The study was conducted within the Birmingham National Institute for Health Research (NIHR) / Wellcome Trust (WT) Clinical Research Facility (CRF) (Birmingham, United Kingdom). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. Disclosures – LH, DJ, RB. have received research grants and speakers fees from J Hofman La Roche. LH, RB, DJ, MM have been involved in studies in which rituximab was given free of charge by Roche and Mycophenolate was given free of charge by Vifor (previously Aspreva). Address for correspondence: Prof Lorraine Harper Institute of Clinical Sciences, University of Birmingham, Birmingham B15 2TT Email: L.Harper@bham.ac.uk
Katie Druce
From the Institute of Clinical Sciences, University of Birmingham, Birmingham B15 2TT; Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom; Department of Medicine, University of Cambridge; Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow. This work was supported by Vifor Pharma (previously Aspreva Pharmaceuticals) who provided a research grant to cover the trial and MMF costs for MYCYC and F. Hoffmann–La Roche who provided the rituximab and a research grant that contributed to trial costs for RITUXIVAS. The funding sources had no role in the design and conduct of the study, collection, management, analysis and interpretation of the data, preparation, review, or approval of the manuscript, and decision to submit the manuscript for publication. The study was conducted within the Birmingham National Institute for Health Research (NIHR) / Wellcome Trust (WT) Clinical Research Facility (CRF) (Birmingham, United Kingdom). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. Disclosures – LH, DJ, RB. have received research grants and speakers fees from J Hofman La Roche. LH, RB, DJ, MM have been involved in studies in which rituximab was given free of charge by Roche and Mycophenolate was given free of charge by Vifor (previously Aspreva). Address for correspondence: Prof Lorraine Harper Institute of Clinical Sciences, University of Birmingham, Birmingham B15 2TT Email: L.Harper@bham.ac.uk
Dimitrios Chanouzas
From the Institute of Clinical Sciences, University of Birmingham, Birmingham B15 2TT; Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom; Department of Medicine, University of Cambridge; Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow. This work was supported by Vifor Pharma (previously Aspreva Pharmaceuticals) who provided a research grant to cover the trial and MMF costs for MYCYC and F. Hoffmann–La Roche who provided the rituximab and a research grant that contributed to trial costs for RITUXIVAS. The funding sources had no role in the design and conduct of the study, collection, management, analysis and interpretation of the data, preparation, review, or approval of the manuscript, and decision to submit the manuscript for publication. The study was conducted within the Birmingham National Institute for Health Research (NIHR) / Wellcome Trust (WT) Clinical Research Facility (CRF) (Birmingham, United Kingdom). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. Disclosures – LH, DJ, RB. have received research grants and speakers fees from J Hofman La Roche. LH, RB, DJ, MM have been involved in studies in which rituximab was given free of charge by Roche and Mycophenolate was given free of charge by Vifor (previously Aspreva). Address for correspondence: Prof Lorraine Harper Institute of Clinical Sciences, University of Birmingham, Birmingham B15 2TT Email: L.Harper@bham.ac.uk
Matthew Morgan
From the Institute of Clinical Sciences, University of Birmingham, Birmingham B15 2TT; Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom; Department of Medicine, University of Cambridge; Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow. This work was supported by Vifor Pharma (previously Aspreva Pharmaceuticals) who provided a research grant to cover the trial and MMF costs for MYCYC and F. Hoffmann–La Roche who provided the rituximab and a research grant that contributed to trial costs for RITUXIVAS. The funding sources had no role in the design and conduct of the study, collection, management, analysis and interpretation of the data, preparation, review, or approval of the manuscript, and decision to submit the manuscript for publication. The study was conducted within the Birmingham National Institute for Health Research (NIHR) / Wellcome Trust (WT) Clinical Research Facility (CRF) (Birmingham, United Kingdom). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. Disclosures – LH, DJ, RB. have received research grants and speakers fees from J Hofman La Roche. LH, RB, DJ, MM have been involved in studies in which rituximab was given free of charge by Roche and Mycophenolate was given free of charge by Vifor (previously Aspreva). Address for correspondence: Prof Lorraine Harper Institute of Clinical Sciences, University of Birmingham, Birmingham B15 2TT Email: L.Harper@bham.ac.uk
Rachel Jones
From the Institute of Clinical Sciences, University of Birmingham, Birmingham B15 2TT; Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom; Department of Medicine, University of Cambridge; Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow. This work was supported by Vifor Pharma (previously Aspreva Pharmaceuticals) who provided a research grant to cover the trial and MMF costs for MYCYC and F. Hoffmann–La Roche who provided the rituximab and a research grant that contributed to trial costs for RITUXIVAS. The funding sources had no role in the design and conduct of the study, collection, management, analysis and interpretation of the data, preparation, review, or approval of the manuscript, and decision to submit the manuscript for publication. The study was conducted within the Birmingham National Institute for Health Research (NIHR) / Wellcome Trust (WT) Clinical Research Facility (CRF) (Birmingham, United Kingdom). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. Disclosures – LH, DJ, RB. have received research grants and speakers fees from J Hofman La Roche. LH, RB, DJ, MM have been involved in studies in which rituximab was given free of charge by Roche and Mycophenolate was given free of charge by Vifor (previously Aspreva). Address for correspondence: Prof Lorraine Harper Institute of Clinical Sciences, University of Birmingham, Birmingham B15 2TT Email: L.Harper@bham.ac.uk
David Jayne
From the Institute of Clinical Sciences, University of Birmingham, Birmingham B15 2TT; Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom; Department of Medicine, University of Cambridge; Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow. This work was supported by Vifor Pharma (previously Aspreva Pharmaceuticals) who provided a research grant to cover the trial and MMF costs for MYCYC and F. Hoffmann–La Roche who provided the rituximab and a research grant that contributed to trial costs for RITUXIVAS. The funding sources had no role in the design and conduct of the study, collection, management, analysis and interpretation of the data, preparation, review, or approval of the manuscript, and decision to submit the manuscript for publication. The study was conducted within the Birmingham National Institute for Health Research (NIHR) / Wellcome Trust (WT) Clinical Research Facility (CRF) (Birmingham, United Kingdom). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. Disclosures – LH, DJ, RB. have received research grants and speakers fees from J Hofman La Roche. LH, RB, DJ, MM have been involved in studies in which rituximab was given free of charge by Roche and Mycophenolate was given free of charge by Vifor (previously Aspreva). Address for correspondence: Prof Lorraine Harper Institute of Clinical Sciences, University of Birmingham, Birmingham B15 2TT Email: L.Harper@bham.ac.uk
Neil Basu
From the Institute of Clinical Sciences, University of Birmingham, Birmingham B15 2TT; Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom; Department of Medicine, University of Cambridge; Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow. This work was supported by Vifor Pharma (previously Aspreva Pharmaceuticals) who provided a research grant to cover the trial and MMF costs for MYCYC and F. Hoffmann–La Roche who provided the rituximab and a research grant that contributed to trial costs for RITUXIVAS. The funding sources had no role in the design and conduct of the study, collection, management, analysis and interpretation of the data, preparation, review, or approval of the manuscript, and decision to submit the manuscript for publication. The study was conducted within the Birmingham National Institute for Health Research (NIHR) / Wellcome Trust (WT) Clinical Research Facility (CRF) (Birmingham, United Kingdom). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. Disclosures – LH, DJ, RB. have received research grants and speakers fees from J Hofman La Roche. LH, RB, DJ, MM have been involved in studies in which rituximab was given free of charge by Roche and Mycophenolate was given free of charge by Vifor (previously Aspreva). Address for correspondence: Prof Lorraine Harper Institute of Clinical Sciences, University of Birmingham, Birmingham B15 2TT Email: L.Harper@bham.ac.uk
Lorraine Harper
From the Institute of Clinical Sciences, University of Birmingham, Birmingham B15 2TT; Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom; Department of Medicine, University of Cambridge; Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow. This work was supported by Vifor Pharma (previously Aspreva Pharmaceuticals) who provided a research grant to cover the trial and MMF costs for MYCYC and F. Hoffmann–La Roche who provided the rituximab and a research grant that contributed to trial costs for RITUXIVAS. The funding sources had no role in the design and conduct of the study, collection, management, analysis and interpretation of the data, preparation, review, or approval of the manuscript, and decision to submit the manuscript for publication. The study was conducted within the Birmingham National Institute for Health Research (NIHR) / Wellcome Trust (WT) Clinical Research Facility (CRF) (Birmingham, United Kingdom). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. Disclosures – LH, DJ, RB. have received research grants and speakers fees from J Hofman La Roche. LH, RB, DJ, MM have been involved in studies in which rituximab was given free of charge by Roche and Mycophenolate was given free of charge by Vifor (previously Aspreva). Address for correspondence: Prof Lorraine Harper Institute of Clinical Sciences, University of Birmingham, Birmingham B15 2TT Email: L.Harper@bham.ac.uk
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Accepted manuscript
The Longitudinal Course of Fatigue in Anca Associated Vasculitis
Lucy O’Malley, Katie Druce, Dimitrios Chanouzas, Matthew Morgan, Rachel Jones, David Jayne, Neil Basu, Lorraine Harper
The Journal of Rheumatology Jul 2019, jrheum.190113; DOI: 10.3899/jrheum.190113